跳至主要内容
临床试验/EUCTR2017-000996-98-BE
EUCTR2017-000996-98-BE进行中(未招募)1 期

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome - AEGIS-II / ApoA-I Event reducinG in Ischemic Syndromes II

CSL Behring LLC0 个研究点目标入组 17,400 人开始时间: 2018年5月25日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
17,400

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Male or female least 18 years of age
  • 2. Evidence of myocardial necrosis, consistent with type (spontaneous) MI
  • 3. No suspicion of acute kidney injury
  • 4. Evidence of multivessel coronary artery disease and at least 1 of the following established risk factors:age = 65 years, prior history of MI, diabetes mellitus, or peripheral artery disease
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 6960
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 10440

排除标准

  • 1. Ongoing hemodynamic instability
  • 2. Evidence of hepatobiliary disease
  • 3. Evidence of severe chronic kidney disease
  • 4. Plan to undergo scheduled coronary artery bypass graft surgery
  • 5. Known history of allergies, hypersensitivity, or deficiencies to soy bean, peanut or albumin

研究者

相似试验